E36: Patients First? Why Pharma Sleeping on GenAI Costs Lives
Key Insights
Verified facts from yesterday's Nature paper and last week's industry announcements.
Breaking down:
- 8 successful cancer drug candidates from 9 attempts (published yesterday, peer-reviewed)
- Traditional Phase 2 success: 28-40% | AI-enhanced: 89% (CDK2 target Pfizer couldn't crack)
- 1 billion molecular evaluations per week vs your 1,000 per year
- "Novel scaffolds": How AI generates entirely new patent families (20-year monopolies)
- The companies already shipping: Atomwise, BenevolentAI, Recursion (with Phase 2 proof)
- Why "it's not our core competency" is a death sentence for your pipeline
Plus: The 6-month committee meeting that costs 500 cancer patients their lives.
For access to the full transcript, join our community!
get started
